Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

Developing tools to assess Americans’ risk of developing and dying from cardiovascular disease

The Problem

Cardiovascular disease is one of the most lethal conditions in the United States, yet researchers lack the tools needed to assess an individual’s risk of developing or dying from this disease.

The Solution

This project will establish “normal” reference levels of several biomarkers and determine these biomarkers’ ability to predict deaths from cardiovascular disease in the general U.S. population, as well as in various demographic subgroups.

Overview

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges, and to generate the epidemiologic basis, for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The project will measure a panel of biomarkers in almost 30,000 individuals in a national study and will provide key reference data regarding novel biomarkers for cardiovascular risk stratification. This reference data will in turn inform U.S. clinical and laboratory guidelines for cardiovascular diseases.

Goals

Define the reference ranges of several biomarkers (i.e., hs-cTnT, hs-cTnI and NT-proBNP) in a healthy subgroup of young adults (N=1,938) and describe age-, gender- and race-specific population values.
Characterize the associations of these biomarkers (i.e., hs-cTnT, hs-cTnI and NT-proBNP) with cardiovascular and total mortality in the U.S. population without clinical cardiovascular disease and compare hs-cTnT to hs-cTnI head-to-head for their ability to predict mortality risk.

Results & Accomplishments

Peer reviewed publications and final dataset made publicly available on NHANES' website

Publications

Partners

Public-Sector Partners

Private-Sector Partners

Academic Partners

*Provided financial or in-kind support for this program.

FNIH Contact

Helen Heymann, MMSC, Senior Scientific Project Manager, Metabolic Disorders; hheymann@fnih.org

Associations of Glycated Albumin and HbA1c with Chronic Kidney Disease in US Adults. Hyunju Kim , Olive Tang, Casey M. Rebholz, Morgan E. Grams, Josef Coresh, Robert H. Christenson, and Elizabeth Selvin. JALM | 1–12 | 00:0 | 2022

Amelia S. Wallace1,2 | Mary R. Rooney1,2 | Tammy M. Brady3 |Justin B. Echouffo-Tcheugui4 | Robert Christenson5 | Morgan E. Grams1,2,4 | Elizabeth Selvin1,2I. The performance of glycated albumin as a biomarker of hyperglycemia and cardiometabolic risk in children and adolescents in the United States. Wiley. Received: 20 July 2021 Revised: 1 October 2021 Accepted: 23 October 2021 DOI: 10.1111/pedi.13281

Michael Fang, Natalie Daya , Josef Coresh, Robert H. Christenson, and Elizabeth Selvin, Glycated Albumin for the Diagnosis of Diabetes in US Adults. Endocrinology and Metabolism. Clinical Chemistry 00:01–9 (2021)

Mary R. Rooney, Natalie Daya, Olive Tang, John William McEvoy, Josef Coresh,, Robert H. Christenson, and Elizabeth Selvin. Glycated Albumin and Risk of Mortality in the US Adult Population. Epidemiological Studies. Clinical Chemistry 00:0, 1–13 (2021).

Caitlin W. Hicks, Dan Wang , Kunihiro Matsushita , John W. McEvoy, Robert Christenson, Elizabeth Selvin. Glycated albumin and HbA1c as markers of lower extremity disease in US adults with and without diabetes. Diabetes Research and Clinical Practice. 2022. 109212